{"id":"hfa-mdi","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HFA MDI refers to a drug delivery system rather than a specific active pharmaceutical ingredient. HFA (hydrofluoroalkane) propellants replaced chlorofluorocarbon (CFC) propellants in metered-dose inhalers due to environmental concerns. The MDI (metered-dose inhaler) mechanism uses pressurized gas to aerosolize and deliver a precise dose of medication to the lungs for local or systemic absorption.","oneSentence":"HFA MDI is a hydrofluoroalkane-based metered-dose inhaler formulation that delivers aerosolized medication directly to the respiratory tract.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:10.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT06563102","phase":"PHASE4","title":"Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-11","conditions":"Mild Asthma","enrollment":101},{"nctId":"NCT05755932","phase":"PHASE3","title":"Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-14","conditions":"Mucociliary Clearance","enrollment":35},{"nctId":"NCT06502366","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-22","conditions":"Asthma","enrollment":422},{"nctId":"NCT05850494","phase":"PHASE3","title":"Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-05-02","conditions":"Asthma","enrollment":52},{"nctId":"NCT05573464","phase":"PHASE3","title":"A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-09-27","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":559},{"nctId":"NCT04901715","phase":"EARLY_PHASE1","title":"Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2021-06-10","conditions":"Primary Ciliary Dyskinesia","enrollment":27},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06075095","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-11","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":297},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT06723756","phase":"PHASE1","title":"A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-23","conditions":"Healthy Participants","enrollment":105},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT01396278","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":9},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT06618105","phase":"PHASE3","title":"Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd","status":"NOT_YET_RECRUITING","sponsor":"Macleods Pharmaceuticals Ltd","startDate":"2024-10-15","conditions":"Mild Asthma","enrollment":144},{"nctId":"NCT00070707","phase":"PHASE4","title":"Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-03","conditions":"Rhinitis, Allergic, Seasonal, Asthma","enrollment":188},{"nctId":"NCT06139991","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-16","conditions":"Heathy Participants","enrollment":66},{"nctId":"NCT01471340","phase":"PHASE4","title":"A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-01-09","conditions":"Asthma","enrollment":11744},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT02741271","phase":"PHASE3","title":"Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2016-05-11","conditions":"Asthma","enrollment":181},{"nctId":"NCT04803734","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2021-03-19","conditions":"Healthy","enrollment":60},{"nctId":"NCT05300087","phase":"NA","title":"Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2022-02-24","conditions":"Healthy","enrollment":60},{"nctId":"NCT00267917","phase":"PHASE4","title":"Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01-17","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":13},{"nctId":"NCT00153075","phase":"PHASE4","title":"Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09-26","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":19},{"nctId":"NCT03453112","phase":"PHASE3","title":"Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-10-09","conditions":"Asthma","enrollment":494},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00458835","phase":"PHASE4","title":"Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)","status":"COMPLETED","sponsor":"Covis Pharma S.à.r.l.","startDate":"2007-04","conditions":"Allergic Rhinitis","enrollment":30},{"nctId":"NCT04600505","phase":"PHASE1","title":"A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":47},{"nctId":"NCT00530062","phase":"PHASE4","title":"Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-07-25","conditions":"Asthma","enrollment":49},{"nctId":"NCT01397162","phase":"PHASE2","title":"Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-21","conditions":"Asthma","enrollment":29},{"nctId":"NCT01397201","phase":"PHASE2","title":"Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2011-07-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT01615874","phase":"PHASE2","title":"Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)","status":"WITHDRAWN","sponsor":"Organon and Co","startDate":"2013-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT03084718","phase":"PHASE2","title":"An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"Asthma","enrollment":610},{"nctId":"NCT05152355","phase":"PHASE4","title":"Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2019-04-22","conditions":"Asthma","enrollment":270},{"nctId":"NCT00054964","phase":"PHASE2","title":"Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2003-03-31","conditions":"Asthma","enrollment":14},{"nctId":"NCT00071552","phase":"PHASE4","title":"Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01-31","conditions":"Asthma","enrollment":49},{"nctId":"NCT00085774","phase":"PHASE3","title":"Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-06-30","conditions":"Exercise-induced Bronchospasm","enrollment":24},{"nctId":"NCT00094016","phase":"PHASE3","title":"Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-10-31","conditions":"Asthma","enrollment":440},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT00577655","phase":"PHASE3","title":"Albuterol HFA MDI in Pediatric Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2007-08","conditions":"Asthma","enrollment":103},{"nctId":"NCT02315131","phase":"PHASE1","title":"Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD","enrollment":53},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT01058863","phase":"PHASE2","title":"A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-02","conditions":"Asthma","enrollment":72},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT01343745","phase":"PHASE2","title":"Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2008-02","conditions":"Mild Persistent Asthma","enrollment":18},{"nctId":"NCT03879837","phase":"PHASE3","title":"Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-03-25","conditions":"Asthma","enrollment":1902},{"nctId":"NCT02743013","phase":"PHASE1","title":"Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04","conditions":"COPD","enrollment":50},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT02584257","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2016-04","conditions":"Mild Persistent Asthma","enrollment":217},{"nctId":"NCT04051710","phase":"PHASE3","title":"Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH","status":"COMPLETED","sponsor":"Aurobindo Pharma Ltd","startDate":"2019-03-12","conditions":"Bronchial Asthma","enrollment":1550},{"nctId":"NCT01280175","phase":"PHASE1","title":"Foster With or Without Charcoal Block or Aerochamber Plus","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2006-12","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT03364608","phase":"PHASE2","title":"Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT03371459","phase":"PHASE2","title":"Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-29","conditions":"Asthma","enrollment":46},{"nctId":"NCT01194700","phase":"PHASE4","title":"Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2009-11","conditions":"Asthma","enrollment":19},{"nctId":"NCT03643874","phase":"PHASE2","title":"Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"Concentrx Pharmaceuticals, Inc.","startDate":"2018-06-30","conditions":"Asthma","enrollment":13},{"nctId":"NCT03373409","phase":"PHASE1","title":"Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI","status":"COMPLETED","sponsor":"Concentrx Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Asthma","enrollment":12},{"nctId":"NCT01143051","phase":"PHASE1, PHASE2","title":"Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":24},{"nctId":"NCT02182869","phase":"PHASE2","title":"Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2001-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":7},{"nctId":"NCT01460511","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of E004 in Children With Asthma","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2011-10","conditions":"Asthma","enrollment":70},{"nctId":"NCT01350128","phase":"PHASE2","title":"PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2011-05-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":103},{"nctId":"NCT02045953","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-29","conditions":"Asthma","enrollment":21},{"nctId":"NCT01025648","phase":"PHASE1, PHASE2","title":"Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2009-12","conditions":"Asthma","enrollment":9},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT03480997","phase":"PHASE1","title":"Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD","status":"COMPLETED","sponsor":"Pneuma Respiratory, Inc","startDate":"2016-12-27","conditions":"COPD","enrollment":46},{"nctId":"NCT00826748","phase":"PHASE4","title":"Effect of Inhaled Steroids on Gene Expression in the Lungs - 2","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2010-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":24},{"nctId":"NCT00370097","phase":"PHASE1","title":"FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-30","conditions":"Asthma","enrollment":16},{"nctId":"NCT01188577","phase":"PHASE1, PHASE2","title":"Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-08","conditions":"Asthma, Bronchospasm, Wheezing","enrollment":23},{"nctId":"NCT01189396","phase":"PHASE2","title":"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":27},{"nctId":"NCT02113436","phase":"PHASE4","title":"Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-01","conditions":"Asthma","enrollment":300},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT00384189","phase":"PHASE3","title":"A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma","enrollment":1080},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT01184118","phase":"NA","title":"DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-03","conditions":"Lung Disease","enrollment":36},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT00532584","phase":"PHASE4","title":"Effect of Steroids on Gene Expression in the Healthy Smokers Lungs","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2011-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT02150499","phase":"PHASE3","title":"A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-07","conditions":"Asthma","enrollment":18},{"nctId":"NCT01703624","phase":"PHASE2","title":"Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Prosonix Limited","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":37},{"nctId":"NCT01737892","phase":"PHASE1, PHASE2","title":"Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults","status":"TERMINATED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2012-11","conditions":"Asthma","enrollment":21},{"nctId":"NCT01737905","phase":"PHASE3","title":"Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2012-10","conditions":"Asthma","enrollment":28},{"nctId":"NCT01357642","phase":"PHASE3","title":"Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2011-07","conditions":"Asthma","enrollment":373},{"nctId":"NCT02466503","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-08","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT02165046","phase":"PHASE1","title":"Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2012-02","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":24},{"nctId":"NCT02165033","phase":"PHASE1","title":"Multiple-dose Pharmacokinetics Study of \"SYN006 HFA MDI\" Administered Orally to Healthy Volunteers","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2012-11","conditions":"Asthma","enrollment":16},{"nctId":"NCT02162784","phase":"PHASE2","title":"Efficacy Study of SYN006 HFA MDI in Asthma Patients","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2013-02","conditions":"Asthma","enrollment":39},{"nctId":"NCT00449046","phase":"PHASE3","title":"Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT01019694","phase":"PHASE3","title":"Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":470},{"nctId":"NCT02220673","phase":"PHASE1","title":"Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Asthma","enrollment":61},{"nctId":"NCT00809757","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Asthma","enrollment":197},{"nctId":"NCT02176200","phase":"PHASE3","title":"Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2003-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ABDOMINAL PAIN LOWER"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BLOOD SODIUM INCREASED"},{"count":1,"reaction":"BLOOD UREA INCREASED"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DEHYDRATION"}],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Propellant in MDI"],"phase":"phase_3","status":"active","brandName":"HFA MDI","genericName":"HFA MDI","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}